<DOC>
	<DOC>NCT00277823</DOC>
	<brief_summary>The purpose of this study is to compare the antidepressant efficacy, safety, and tolerability of DVS-SR in subjects receiving daily doses of 50 mg or 100 mg of DVS-SR versus subjects receiving placebo.</brief_summary>
	<brief_title>Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Clinical diagnosis of major depressive disorder Must be able to swallow tablets Must be at least 18 years of age. Clinical diagnosis of other psychiatric disorders Significant risk of suicide Unstable medical conditions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Depression</keyword>
	<keyword>Adult</keyword>
	<keyword>Outpatients</keyword>
</DOC>